Bruker (NASDAQ:BRKR) Updates Q2 2025 Earnings Guidance

Bruker (NASDAQ:BRKR - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of 0.320-0.340 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $795.0 million-$798.0 million, compared to the consensus revenue estimate of $810.4 million.

Analyst Ratings Changes

A number of research analysts have recently commented on BRKR shares. The Goldman Sachs Group lowered their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus decreased their target price on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Barclays decreased their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Citigroup downgraded Bruker from a "strong-buy" rating to a "hold" rating and decreased their target price for the company from $50.00 to $40.00 in a research note on Thursday, May 22nd. Finally, Bank of America decreased their target price on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Bruker presently has an average rating of "Hold" and an average price target of $52.89.

Bruker Trading Up 8.9%

Shares of NASDAQ:BRKR traded up $3.17 during midday trading on Tuesday, hitting $38.80. The company had a trading volume of 4,732,781 shares, compared to its average volume of 1,839,491. Bruker has a 12 month low of $34.10 and a 12 month high of $72.94. The company has a current ratio of 1.57, a quick ratio of 0.74 and a debt-to-equity ratio of 1.13. The stock has a market cap of $5.88 billion, a price-to-earnings ratio of 74.62, a PEG ratio of 2.73 and a beta of 1.18. The firm has a fifty day simple moving average of $39.43 and a 200 day simple moving average of $44.79.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. The firm had revenue of $801.40 million for the quarter, compared to analyst estimates of $763.83 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The company's revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. On average, analysts predict that Bruker will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date was Monday, June 16th. Bruker's dividend payout ratio is currently 38.46%.

Insider Activity

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction on Friday, June 6th. The shares were purchased at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 27.30% of the company's stock.

Hedge Funds Weigh In On Bruker

Several institutional investors and hedge funds have recently made changes to their positions in BRKR. Goldman Sachs Group Inc. grew its position in Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after buying an additional 758,301 shares in the last quarter. Royal Bank of Canada grew its position in Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after buying an additional 9,501 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock worth $15,285,000 after buying an additional 9,235 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Bruker during the first quarter worth approximately $262,000. Finally, Focus Partners Wealth grew its position in Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock worth $469,000 after buying an additional 6,008 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.